NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. (NBSE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
nbse · stock forecast · 6 analysts (3M) · FMP · updated Feb 27, 2025
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.38
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · NBSE · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-10-21 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2022-10-18 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2022-10-17 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2022-08-12 | Chardan Capital | Maintains | Buy→Buy |
| 2022-05-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-05-13 | Chardan Capital | Maintains | Buy→Buy |
| 2021-06-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-02-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-06-16 | RBC Capital | Maintains | Outperform→Outperform |
| 2020-04-01 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on NeuBase Therapeutics, Inc. (NBSE) stock. Of the recent 16 rating actions, 0 were upgrades and 3 were downgrades. 6 analysts currently cover NBSE.
Analyst Recommendation Trends
NBSE analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$8M
EPS This Year
$-7.29
EPS Next Year
$-1.92
↓ 73.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast NBSE EPS of $-7.29 for the current fiscal year, based on estimates from 1 analysts. The NBSE revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The NBSE stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NBSE price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
NeuBase Therapeutics, Inc. trades on NASDAQ under the ticker NBSE. The NBSE stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
NBSE forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month NBSE price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.38.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.